Muddy Waters CEO Carson Block picked Grifols (GRFS) as a short for the Robin Hood Foundation’s stock picking contest. However, said in an ...

Grifols revenue and EBITDA growth, improved leverage ratio, and significant liquidity highlight its resilience and potential for future profitability. Learn more on GRFS stock here.

Spanish drugmaker Grifols reported on Wednesday a net profit of 157 million euros ($165.02 million) for 2024 on revenues of 7.21 billion euros, up 10.2% from a year earlier and above its target for 7% ...

Spanish drugmaker Grifols said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in the coming years as it aims to leave behind a tumultuous 2024 when it lost ...

Grifols has announced positive results from its phase 2/3 clinical trial evaluating the efficacy and safety of intravenous ...

Carson Block of Muddy Waters announced Grifols (GRFS) as a short idea for the Robin Hood contest, according to Bloomberg.Light Up your ...

Grifols has shared positive results from its clinical trial evaluating the efficacy and safety of intravenous immunoglobulin to treat patients with PPS.

In response, Grifols, a global leader in plasma science and the production of plasma-derived medicines, has embarked on a groundbreaking program in partnership with The Michael J. Fox Foundation ...

In this article, we are going to take a look at where Grifols, S.A. (NASDAQ:GRFS) stands against the other pharma stocks. Healthcare, which includes numerous businesses that offer patient care ...

More than two dozen people rallied on Monday against a new for-profit clinic in Whitby that pays people for plasma donations.

Hamilton was declared a paid-plasma-free zone in June, but Canadian Blood Services and Spanish health-care company Grifols ...

Grifols has announced positive results from its phase 2/3 clinical trial evaluating the efficacy and safety of intravenous immunoglobulin (IVIG) to treat post-polio syndrome (PPS). The study showed ...